Genmab A/S - American Depositary Shares (NQ:GMAB)

34.75 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

April 29, 2024

From Genmab A/S

Via Business Wire

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

April 29, 2024

From Pfizer Inc.

Via Business Wire

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market ↗

April 25, 2024

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

Via Investor's Business Daily

NASDAQ:GMAB is not too expensive for the growth it is showing. ↗

April 11, 2024

Via Chartmill

Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock? ↗

March 28, 2024

Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout.

Via Chartmill

Analyst Ratings For Genmab ↗

March 26, 2024

Via Benzinga

ProfoundBio Discovers The Joys Of Having A Wealthy Owner ↗

April 08, 2024

Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a...

Via Benzinga

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio ↗

April 03, 2024

Genmab is buying a privately held company focused on antibody drug conjugates.

Via Investor's Business Daily

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

April 03, 2024

From Genmab A/S

Via Business Wire

4 Analysts Assess Genmab: What You Need To Know ↗

February 20, 2024

Via Benzinga

Earnings Outlook For Genmab ↗

February 13, 2024

Via Benzinga

NASDAQ:GMAB, a strong growth stock, setting up for a breakout. ↗

February 08, 2024

Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

March 21, 2024

For those who appreciate growth without the sticker shock, GENMAB A/S -SP ADR (NASDAQ:GMAB) is worth considering.

Via Chartmill

Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

March 05, 2024

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

February 29, 2024

While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.

Via Chartmill

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

February 27, 2024

From Genmab A/S

Via Business Wire

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗

February 08, 2024

While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.

Via Chartmill

Cracking The Code: Understanding Analyst Reviews For Genmab ↗

January 29, 2024

Via Benzinga

Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB. ↗

January 18, 2024

NASDAQ:GMAB is showing good growth, while it is not too expensive.

Via Chartmill

9 Analysts Have This to Say About Genmab ↗

November 28, 2023

Via Benzinga

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

February 02, 2024

From Genmab A/S

Via Business Wire

What's Going On With Danish Healthcare Firm Genmab Stock? ↗

January 23, 2024

Genmab's legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth.

Via Benzinga

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer

January 09, 2024

From Genmab A/S

Via Business Wire

TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

January 09, 2024

From Pfizer Inc.

Via Business Wire

NASDAQ:GMAB stands out as a growth opportunity that won't break the bank. ↗

December 26, 2023

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.

Via Chartmill

Oracle Reports Weak Sales, Joins Kinetik, Lucid Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

December 12, 2023

U.S. stock futures were higher this morning, with the Dow Jones futures gaining over 50 points on Tuesday.

Via Benzinga

Topics Stocks

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

December 09, 2023

From Genmab A/S

Via Business Wire

In the world of growth stocks, NASDAQ:GMAB shines as a value proposition. ↗

December 05, 2023

Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).

Via Chartmill

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

November 27, 2023

From Genmab A/S

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.